|
主治癌症/治療範圍
|
FDA 認可年份
|
藥名
|
|
Acute Leukemia急性白血病
|
||
|
Acute Lymphocytic Leukemia
急性淋巴性白血病 |
2012
|
Marqibo (vinCRIStine sulfate LIPOSOME injection)
|
|
Acute Lymphocytic Leukemia
急性淋巴性白血病 |
2014
|
Blincyto (blinatumomab)
|
|
Chronic Leukemia 慢性白血病
|
|
|
|
Chronic lymphocytic Leukemia
慢性淋巴性白血病 |
2013
|
Gazyva (oblintuzumab)
|
|
Chronic Lymphocytic Leukemia, Follicular B
cell lymphoma, small lymphocytic lymphoma |
2014
|
Zydelig (idelalisib)
|
|
Chronic lymphocytic Leukemia
慢性淋巴性白血病 |
2014
|
Imbruvica (ibrutinib)
|
|
Chronic Myeloid Leukemia
慢性骨髓性白血病 |
2012
|
Bosulif (bosutinib)
|
|
Chronic Myeloid Leukemia
慢性骨髓性白血病 |
2012
|
Iclusig (ponatinib)
|
|
Chronic Myeloid Leukemia
慢性骨髓性白血病 |
2012
|
Synribo (omacetaxine mepesuccinate)
|
|
Multiple Myeloma 多發性骨髓瘤
|
||
|
Multiple Myeloma
|
2012
|
Kyprolis (carfizomib)
|
|
Multiple Myeloma
|
2013
|
1) Pomalyst (pomalidomide)
2) Revlimid (lenalidomide) |
|
Malignant Lymphoma 惡性淋巴瘤
|
|
|
|
Hodgkin’s lymphoma (何傑金氏淋巴瘤) /
Anaplastic large cell lymphoma (間變性大細胞淋巴瘤) |
2011
|
Adcetris (brentuximab vendotin)
|
|
Mantle Cell Lymphoma (套細胞淋巴瘤)
|
2013
|
1) Revlimid (lenalidomide)
2) Imbruvica (ibrutinib) |
|
Follicular B cell Lymphoma (濾泡性淋巴瘤)/
Small Lymphocytic Lymphoma (小淋巴细胞淋巴瘤) |
2014
|
Zydelig (idelalisib)
|
|
Peripheral T cell Lymphoma (外周T细胞淋巴瘤)
|
2014
|
Beleodaq (belinostat)
|
|
Lung Cancer 肺癌
|
||
|
ALK + Non small cell Lung cancer (ALK + 非小细胞肺癌)
|
2011
|
Xalkori (crizotinib)
|
|
Lung Cancer (肺癌)
|
2012
|
Abraxane (paclitaxel protein-bound)
|
|
EGFR mutation + lung cancer (表皮生長因子受體+ 肺癌)
|
2013
|
Gilotrif (afatinib)
|
|
ALK + Non small cell Lung cancer (ALK + 非小细胞肺癌)
|
2014
|
Zykadia (ceritinib)
|
| Squamous cell lung cancer (扁平上皮細胞肺癌) | 2015 | Opdivo (Nivolumab) |
|
Breast Cancer 乳癌
|
||
|
Breast Cancer (乳癌)
|
2010
|
Halaven (eribulin mesylate)
|
|
HER 2+ Breast Cancer (Her 2 + 乳癌)
|
2012
|
Perjeta (pertuzumab)
|
|
Hormone receptor + Breast Cancer (激素受體 + 乳癌)
|
2012
|
Afinitor (everolimus)
|
|
HER 2+ Breast Cancer (Her 2 + 乳癌)
|
2013
|
Kadcyla (ado-trastuzumab emtansine)
|
|
ER +, HER 2 – Breast Cancer
(ER +, Her 2 - 乳癌) |
2015
|
Ibrance (palbociclib)
|
|
Ovary Cancer 卵巢癌
|
||
|
BRCA mutated Ovary Cancer
|
2014
|
Lynparza (olaparib)
|
|
Prostate Cancer 前列腺癌
|
||
|
Hormone refractory Prostate Cancer
(激素非依賴性前列腺癌) |
2010
|
Provenge (sipuleucel-T)
|
|
Prostate Cancer (前列腺癌)
|
2010
|
Jevtana (cabazitaxel)
|
|
Prostate Cancer (前列腺癌)
|
2011
|
Zytiga (abiraterone acetate)
|
|
castration resistant Prostate Cancer
|
2012
|
Xtandi (enzalutamide)
|
|
Malignant Melanoma皮膚惡性黑色素瘤
|
||
|
BRAF + Melanoma (BRAF + 皮膚黑色素瘤)
|
2011
|
Zelboraf (vemurafenib)
|
|
Melanoma (皮膚黑色素瘤)
|
2011
|
Yervoy (ipilimumab)
|
|
BRAF + Melanoma (BRAF + 皮膚黑色素瘤)
|
2013
|
1) Tafinlar (dabrafenib)
2) Mekinist (trametinib) |
|
Melanoma (皮膚黑色素瘤)
|
2014
|
1) Keytruda (pembrolizumab)
2) Opdivo (nivolumab) |
|
Stomach Cancer 胃癌
|
2014
|
Cyramza (ramucirumab)
|
|
Thyroid Cancer甲狀腺癌
|
||
|
Thyroid Cancer (甲狀腺癌)
|
2011
|
Vandetanib (vandetanib)
|
|
Medullary thyroid cancer (甲状腺髓样癌)
|
2012
|
Cometriq (cabozantinib)
|
|
Sarcoma肉瘤
|
||
|
Soft Tissue Sarcoma (軟組織肉瘤)
|
2012
|
Votrient (pazopanib)
|
|
Colon Cancer 腸癌
|
||
|
Colorectal Cancer (結直腸癌)
|
2012
|
1) Zaltrap (ziv-aflibercept)
2) Stivarga (regorafenib) |
|
Neuroendocrine Tumor神經內分泌腫瘤
|
||
|
Pancreatic Neuroendocrine Tumor
(胃腸胰神經内分泌腫瘤) |
2011
|
Afinitor (everolimus)
|
|
Kidney Cancer 腎癌
|
2012
|
Inlyta (Axitinib)
|
|
Skin Cancer 皮膚癌
|
||
|
Basal cell Carcinoma (基底细胞癌)
|
2012
|
Erivedge (vismodegib)
|
亞太腫瘤綜合中心有限公司